Holmlin R. Erik 4

What Happened
Erik R. Holmlin, President, CEO and Director of Bionano Genomics (BNGO), was granted a derivative award covering 69,484 shares on February 2, 2026. The award is reported at an acquisition price of $0.00 (i.e., no cash paid at grant), and the filing identifies it as a grant/award (transaction code A) rather than an exercised option or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (timely filing).
• Award size: 69,484 shares reported as a derivative award; acquisition price listed as $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote: The award vests monthly over 48 months beginning one month after the vesting commencement date; fully vested on the four‑year anniversary (see footnote F1).
• No sale, exercise, or tax-withholding event reported in this filing.

Context
This was a grant of a derivative award (an option-style award per the filing’s footnote), not an exercise or sale — meaning Holmlin received the right to future shares that will vest over time rather than immediately acquiring freely tradable shares or selling stock. Such grants are common for executive compensation and are intended to align management incentives with long-term company performance; they do not by themselves indicate intent to buy or sell shares in the open market.